

# Azra H Ligon

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11368648/azra-h-ligon-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93  
papers

16,056  
citations

46  
h-index

97  
g-index

97  
ext. papers

18,627  
ext. citations

8.6  
avg, IF

5.57  
L-index

#	Paper	IF	Citations
93	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , <b>2010</b> , 463, 899-905	50.4	2590
92	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 311-9	59.2	2513
91	Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. <i>Nature Genetics</i> , <b>1997</b> , 15, 356-62	36.3	2377
90	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. <i>Nature Genetics</i> , <b>2011</b> , 43, 869-74	36.3	788
89	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2698-704	2.2	677
88	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1283-94	21.7	643
87	CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. <i>Nature</i> , <b>2008</b> , 455, 547-51	50.4	519
86	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2690-7	2.2	472
85	Targetable genetic features of primary testicular and primary central nervous system lymphomas. <i>Blood</i> , <b>2016</b> , 127, 869-81	2.2	317
84	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 835-40	2.2	297
83	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , <b>2014</b> , 46, 462-6	36.3	296
82	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , <b>2016</b> , 1, e87062	9.9	245
81	BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. <i>PLoS ONE</i> , <b>2011</b> , 6, e17948	3.7	228
80	Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2017</b> , 141, 751-758	5	206
79	EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. <i>Cancer Discovery</i> , <b>2014</b> , 4, 956-71	24.4	199
78	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 1011-1022	21.7	182
77	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 942-950	2.2	175

76	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 481-489	2.2	173
75	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , <b>2020</b> , 580, 517-523	50.4	172
74	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 8188-93	11.5	156
73	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. <i>Nature Genetics</i> , <b>2016</b> , 48, 273-82	36.3	154
72	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 649-55	1	144
71	Classical Hodgkin Lymphoma with Reduced $\beta$ 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 910-916	12.5	118
70	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3291-3299	2.2	116
69	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1997-2007	2.2	110
68	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 567-78	1	110
67	Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. <i>American Journal of Human Genetics</i> , <b>2005</b> , 76, 340-8	11	103
66	Genetics of uterine leiomyomata. <i>Genes Chromosomes and Cancer</i> , <b>2000</b> , 28, 235-245	5	97
65	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. <i>JAMA Oncology</i> , <b>2016</b> , 2, 518-22	13.4	95
64	Characterization of apparently balanced chromosomal rearrangements from the developmental genome anatomy project. <i>American Journal of Human Genetics</i> , <b>2008</b> , 82, 712-22	11	84
63	NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract defects. <i>PLoS Genetics</i> , <b>2007</b> , 3, e80	6	80
62	Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. <i>Blood</i> , <b>2014</b> , 124, 291-291	2.2	79
61	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , <b>2016</b> , 22, 723-6	50.5	76
60	Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6430-7	12.9	72
59	Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. <i>Journal of Molecular Diagnostics</i> , <b>2011</b> , 13, 669-77	5.1	69

58	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 741-750	2.2	64
57	Landscape of Genomic Alterations in Pituitary Adenomas. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1841-1851	12.9	64
56	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 535-545	1	60
55	A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, 922-933	6.7	59
54	ORC5L, a new member of the human origin recognition complex, is deleted in uterine leiomyomas and malignant myeloid diseases. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 27137-45	5.4	59
53	ARID1A and TERT promoter mutations in dedifferentiated meningioma. <i>Cancer Genetics</i> , <b>2015</b> , 208, 345-50	5.9	57
52	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1185-96	12.9	54
51	Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. <i>American Journal of Pathology</i> , <b>2010</b> , 176, 1901-13	5.8	53
50	BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2012</b> , 71, 789-94	3.1	51
49	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 269-74	1	47
48	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <i>Oncotarget</i> , <b>2014</b> , 5, 10596-606	3.3	46
47	Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. <i>Neoplasia</i> , <b>2010</b> , 12, 161-72	6.4	46
46	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , <b>2014</b> , 5, 8083-92	3.3	46
45	Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. <i>Cancer Genetics and Cytogenetics</i> , <b>1999</b> , 114, 9-16		45
44	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 986-996	1	39
43	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 1344-55	1	39
42	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1873-83	12.9	38
41	Simultaneous, multilocus FISH analysis for detection of microdeletions in the diagnostic evaluation of developmental delay and mental retardation. <i>American Journal of Human Genetics</i> , <b>1997</b> , 61, 51-9	11	36

40	Molecular and clinicopathologic features of gliomas harboring NTRK fusions. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 107	7.3	36
39	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 1486-96	1	33
38	Disruption of diacylglycerol kinase delta (DGKD) associated with seizures in humans and mice. <i>American Journal of Human Genetics</i> , <b>2007</b> , 80, 792-9	11	33
37	Dysregulation of HMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14 <b>2000</b> , 27, 209-215		28
36	DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. <i>PLoS ONE</i> , <b>2012</b> , 7, e38881	3.7	24
35	Gene for multiple exostoses (EXT2) maps to 11(p11.2p12) and is deleted in patients with a contiguous gene syndrome. <i>American Journal of Medical Genetics Part A</i> , <b>1998</b> , 75, 538-40		21
34	Identification of female carriers for Duchenne and Becker muscular dystrophies using a FISH-based approach. <i>European Journal of Human Genetics</i> , <b>2000</b> , 8, 293-8	5.3	20
33	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. <i>American Journal of Clinical Pathology</i> , <b>2019</b> , 152, 97-108	1.9	17
32	A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1777-1788	1	17
31	PCOLCE deletion and expression analyses in uterine leiomyomata. <i>Cancer Genetics and Cytogenetics</i> , <b>2002</b> , 137, 133-7		16
30	Genomic characterization of recurrent high-grade astroblastoma. <i>Cancer Genetics</i> , <b>2016</b> , 209, 321-30	2.3	15
29	Candidate loci for Zimmermann-Laband syndrome at 3p14.3. <i>American Journal of Medical Genetics, Part A</i> , <b>2007</b> , 143A, 107-11	2.5	15
28	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 908-917	1	14
27	Disruption of a synaptotagmin (SYT14) associated with neurodevelopmental abnormalities. <i>American Journal of Medical Genetics, Part A</i> , <b>2007</b> , 143A, 558-63	2.5	13
26	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. <i>World Neurosurgery</i> , <b>2016</b> , 85, 96-105	2.1	11
25	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , <b>2018</b> , 132, 228-228	2.2	11
24	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , <b>2021</b> , 137, 1353-1364	2.2	11
23	A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 10504-10504	2.2	10

22	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1695-1705	12.9	9
21	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. <i>Diagnostic Pathology</i> , <b>2016</b> , 11, 13	3	8
20	Optic nerve glioma: case series with review of clinical, radiologic, molecular, and histopathologic characteristics. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , <b>2014</b> , 30, 372-6	1.4	7
19	Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. <i>Blood</i> , <b>2014</b> , 124, 289-289	2.2	7
18	Characterization of molecular signatures of supratentorial ependymomas. <i>Modern Pathology</i> , <b>2020</b> , 33, 47-56	9.8	7
17	A Molecularly Integrated Grade for Meningioma. <i>Neuro-Oncology</i> , <b>2021</b> ,	1	7
16	Suppression of transformed phenotype and tumorigenicity after transfer of chromosome 4 into U251 human glioma cells. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 20, 260-267	5	6
15	Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. <i>Journal of NeuroVirology</i> , <b>1998</b> , 4, 217-26	3.9	4
14	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , <b>2016</b> , 128, 2923-2923	2.2	4
13	Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. <i>Modern Pathology</i> , <b>2021</b> , 34, 603-612	9.8	4
12	LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. <i>Neuro-Oncology</i> , <b>2019</b> , 21, ii98-ii99	1	2
11	From Prognostication to Personalized Medicine: Classification of Tumors of the Central Nervous System (CNS) Using Chromosomal Microarrays. <i>Current Genetic Medicine Reports</i> , <b>2017</b> , 5, 117-124	2.2	2
10	Complex cytogenetic rearrangements at the DURS1 locus in syndromic Duane retraction syndrome. <i>Clinical Case Reports (discontinued)</i> , <b>2013</b> , 1, 30	0.7	2
9	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 1579-1579	2.2	2
8	Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors. <i>Cancer Genetics</i> , <b>2020</b> , 243, 19-47	2.3	1
7	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. <i>Cureus</i> , <b>2019</b> , 11, e47261.2	1.2	1
6	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , <b>2015</b> , 126, 176-176	2.2	1
5	LTKB-01. UPDATES ON THE PHASE II AND RE-TREATMENT STUDY OF AZD6244 (SELUMETINIB) FOR CHILDREN WITH RECURRENT OR REFRACTORY PEDIATRIC LOW GRADE GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i214-i214	1	0

- 4 LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial. *Neuro-Oncology*, **2022**, 24, i88-i88 1 0
- 3 Reporting of diagnostic cytogenetic results. *Current Protocols in Human Genetics*, **2011**, Appendix 1, 1D 3.2
- 2 Reporting of diagnostic cytogenetic results. *Current Protocols in Human Genetics*, **2010**, Appendix 1, 1D.1323
- 1 Reporting of diagnostic cytogenetic results. *Current Protocols in Human Genetics*, **2004**, Appendix 1, Appendix 1D 3.2